ADC-189 + itraconazole

ADC-189 + itraconazole is a combination of two pharmaceutical agents. ADC-189 (also known as Deunoxavir marboxil) is a novel oral antiviral drug developed for the treatment of influenza virus infections. It acts as a cap-dependent endonuclease inhibitor targeting the polymerase acidic (PA) protein of influenza viruses and inhibits viral replication by blocking the cap-snatching mechanism essential for viral mRNA synthesis. Preclinical and clinical studies have shown that ADC-189 has potent activity against multiple strains of influenza A and B—including oseltamivir-resistant variants—with favorable pharmacokinetics supporting single-dose oral administration[1][2][3][4][5][6][7]. Itraconazole is an established triazole antifungal agent that inhibits fungal ergosterol synthesis by blocking lanosterol 14α-demethylase; it also exhibits some antiviral and anticancer properties through inhibition of hedgehog signaling and angiogenesis pathways. There are no published data or clinical trials specifically evaluating the combination "ADC-189 + itraconazole" for any indication as of June 2025; this entry describes a hypothetical or investigational combination based on its components.

Other names

ADC189ADC-189ADC 189Deunoxavir marboxilItraconazolum